ArticleJournal of the American Geriatrics Society2019
Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer.
Article in Journal of the American Geriatrics Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The prevalence of frailty among breast cancer patients: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Pooled it
- Characteristics Associated With Functional Changes During Systemic Cancer Treatments: A Systematic Review Focused on Older Adults.Journal of the National Comprehensive Cancer Network : JNCCN · 2021Pooled it
- Resilience in symptom response to cancer treatment: a new lens for examining variable symptom trajectories in older adults with advanced cancer.The oncologist · 2026Trial
- Resiliency among older adults receiving lung cancer treatment (ROAR-LCT): A novel supportive care intervention for older adults with advanced lung cancer.Journal of geriatric oncology · 2024Trial
- Modifiable fall risk factors among older adults with advanced cancer: Secondary analysis of a cluster-randomized clinical trial.Journal of geriatric oncology · 2023Trial
- Bridging the age gap in breast cancer: cluster randomized trial of two decision support interventions for older women with operable breast cancer on quality of life, survival, decision quality, and treatment choices.The British journal of surgery · 2021Trial
- Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- The impact of cancer diagnosis on functional decline in adults aged 50 and older: the US Health and Retirement Study.Journal of cancer survivorship : research and practice · 2026Article
- Article
- A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design.Therapeutic advances in medical oncology · 2026Article
- Article
- Physical health and function trajectories in adults with cancer: psychosocial predictors of class membership.Journal of cancer survivorship : research and practice · 2025Article
- Frailty Trajectories Following Adjuvant Chemotherapy and Mortality in Older Women With Breast Cancer.JAMA network open · 2025Article
- Systemic inflammation and changes in physical well-being in patients with breast cancer: a longitudinal study in community oncology settings.The oncologist · 2025Article
- Physical Health Decline After Chemotherapy or Endocrine Therapy in Breast Cancer Survivors.JAMA network open · 2025Article
- Physical activity and incident cardiovascular disease in breast cancer survivors: the Pathways Study.JNCI cancer spectrum · 2025Article
- Quality of life, fatigue, and muscle strength in women with breast cancer undergoing chemotherapy or hormonal therapy: a case-control study.Frontiers in oncology · 2025Article
- Longitudinal trajectories of a claims-based frailty measure during adjuvant chemotherapy in women with stage I-III breast cancer.The oncologist · 2024Article
- Functional decline in older breast cancer survivors treated with and without chemotherapy and non-cancer controls: results from the Hurria Older PatiEnts (HOPE) prospective study.Journal of cancer survivorship : research and practice · 2024Observational
- A scoping review evaluating physical and cognitive functional outcomes in cancer survivors treated with chemotherapy: charting progress since the 2018 NCI think tank on cancer and aging phenotypes.Journal of cancer survivorship : research and practice · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
objectivesTo analyze self-reported changes in physical function in older women with breast cancer receiving adjuvant chemotherapy.
designSecondary analysis of the Cancer and Leukemia Group B (CALGB) 49907 prospective randomized clinical trial.
settingCALGB institutions in the United States.
participantsWomen aged 65 and older with Stage I to III breast cancer enrolled in CALGB 49907 who had physical function data from before and after receipt of adjuvant chemotherapy (N=256; mean age 71.5, range 65-85). MEASUREMENTS: Participants were administered the physical function subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire before chemotherapy, at the end of chemotherapy, and 12 months after chemotherapy initiation. Functional decline was defined as a more than 10-point decrease from baseline at each time point. Resilience was defined as return to within 10 points of baseline. Multivariable regression was used to examine pretreatment characteristics associated with physical function changes.
resultsOf 42% of participants who had physical function decline from before to the end of chemotherapy, 47% recovered by 12 months (were resilient). Almost one-third experienced functional decline from before chemotherapy to 12 months later. Pretreatment fatigue was a risk factor for functional decline from before to the end of chemotherapy (P=.02). Risk factors for functional decline at 12 months included pretreatment dyspnea (P=.007) and being unmarried (P=.01).
conclusionFunctional decline was common in older women receiving adjuvant chemotherapy for breast cancer in a clinical trial. Although half recovered their physical function, one-third had a clinically meaningful decline at 12 months. Strategies are needed to prevent functional decline in older adults receiving chemotherapy. J Am Geriatr Soc 67:920-927, 2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.